Axolabs logo — SERVING OLIGONUCLEOTIDE THERAPEUTICS

Axolabs

SERVING OLIGONUCLEOTIDE THERAPEUTICS

Founded 2011 Germany Kulmbach, Germany 159 employees Biotechnology, Life Sciences

General Information

Company Name Axolabs
Founded Year 2011
Location Germany Kulmbach, Germany
Employees 159
Industries Biotechnology, Life Sciences
Social

BounceWatch is an independent company data service, not affiliated with Axolabs. To contact Axolabs, visit axolabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Axolabs compare?

A PDF of Axolabs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Axolabs soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Axolabs

Axolabs is a biotechnology startup founded in 2007 with the slogan SERVING OLIGONUCLEOTIDE THERAPEUTICS. It specializes in oligonucleotide or nucleic acid therapeutics, a new class of drugs derived from DNA or RNA. With a strong expertise, Axolabs assists clients in achieving success with these drugs, some of which have already gained approval and are effectively combating previously untreatable diseases. As a part of the LGC Group, Axolabs operates in several locations, including Kulmbach, Germany where it is the leading custom research organization for nucleic acid therapeutics, Berlin, Germany where a state-of-the-art facility for GMP manufacturing of nucleic acid therapeutics will commence operation in 2024, and Petaluma, California, USA where a cGMP production facility exists for oligonucleotide compounds. Their services include bioinformatics, oligonucleotide synthesis, analytics, and in vitro/in vivo analysis. Currently, there is no available information regarding their last investment or investors. As a biotechnology company with a global presence and a focus on pioneering therapeutics, Axolabs presents an interesting prospect for potential investors and venture capitalists.

Business keywords: nucleic acid therapeutics, oligonucleotide, bioinformatics, drug development, pharmaceutical, preclinical research, GMP manufacturing, RNA therapeutics, oligonucleotide synthesis, analytical services

No funding data available for Axolabs yet.

Axolabs Alternatives & Competitors

View All Alternatives
Axolabs vs
环码
环码 China

环码生物致力于 将mRNA科学的全部潜力兑现给患者

Series A
5 employees
Biotechnology, Health Care
Axolabs vs
CatSci Ltd
CatSci Ltd United Kingdom

Excellence in Medicines Development

Growth
100 employees
Biopharma, Biotechnology
Axolabs vs
Creyon Bio
Creyon Bio United States

Delivering RNA breakthroughs. Redefining hope.

Series A
31 employees
Biotechnology, Life Sciences

FAQ About Axolabs

SERVING OLIGONUCLEOTIDE THERAPEUTICS
Axolabs was founded in 2011.
Axolabs is headquartered in Kulmbach, Germany.
Axolabs operates in Biotechnology and Life Sciences. Its work centres on nucleic acid therapeutics, oligonucleotide, bioinformatics and drug development.
Axolabs has approximately 159 employees.
Top alternatives and competitors to Axolabs include 环码, CatSci Ltd, Creyon Bio, Gennao Bio, EnPlusOne Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Axolabs and 环码 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Axolabs, https://bouncewatch.com/company/axolabs, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes